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Mutations in the human calmodulin genes (CALM1, CALM2,
and CALM3) are associated with life-threatening conditions
in childhood, such as idiopathic ventricular ﬁbrillation (VF)
and long QT syndrome (LQTS).1–3 Furthermore, CALM1
mutations were described in a catecholaminergic polymor-
phic ventricular tachycardia (CPVT)-like phenotype.4 Sud-
den unexplained death in the young can be the ﬁrst clinical
manifestation of an underlying arrhythmogenic disorder
such as idiopathic VF.5,6 After an aborted cardiac arrest,
determining the diagnosis begins with a systematic clinical
evaluation. Subsequently, targeted genetic testing may be
considered for genetic conﬁrmation and family screening,7,8
although in the absence of a signiﬁcant family history or
electrocardiographic abnormalities, identiﬁcation of the dis-
ease etiology should be limited to previously recognized
conditions.9
Here we report a novel de novo missense mutation in
CALM1 associated with a phenotype compatible with LQTS
in a child who experienced an aborted ﬁrst-episode cardiac
arrest.Case report
The patient was a 6-year-old, otherwise healthy boy (the
proband) born to seemingly healthy parents. He had a mild
pervasive developmental disorder, with hyperactivity
and mild bronchial asthma. His 5 siblings were healthy,
and there was no family history of syncope or sudden
death.
After a breakfast at his home, the boy suddenly lost
consciousness, collapsed, and was unresponsive. His motherKEYWORDS Arrhythmia; Calmodulin; Long QT; Catecholaminergic poly-
morphic VT; Sudden cardiac arrest
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(http://creativecommons.org/licenses/by-nc-nd/4.0/).called for an ambulance. On arrival, the emergency medical
staff conﬁrmed cardiopulmonary arrest and performed car-
diopulmonary resuscitation. The automated external deﬁb-
rillator showed VF, and the patient was successfully
cardioverted. He was intubated and taken to the local
community hospital. Arterial blood gas analysis showed
combined respiratory and metabolic acidosis thought to be
related to the cardiopulmonary resuscitation. An infusion of
dopamine induced premature ventricular contractions, singly
and in bidirectional couplets, which responded to xylocaine
(Figure 1A). He was then transferred to our hospital for
further evaluation and treatment. VF recurred on arrival at
our hospital’s emergency room. A direct current shock and
150 mg of amiodarone were administered, and he was
transferred to the pediatric intensive care unit. Blood samples
taken at the time of admission showed normal biochemistry,
including normal troponin T and creatinine kinases. Trans-
thoracic echocardiography was normal, with good left
ventricular systolic function. A resting baseline 12-lead
electrocardiogram (ECG) did not indicate any abnormality
such as LQTS or Brugada syndrome. At midnight, he
developed polymorphic ventricular tachycardia, which
degenerated to VF with remarkable QT prolongation
(Figure 1B). When the patient awoke the next day,
torsades de pointes recurred with an increasing heart rate,
despite the continuous infusion of xylocaine (1 mg/kg/h)
(Figure 1C). An additional continuous infusion of propra-
nolol (0.01 mg/kg/h) and mexiletine (0.5 mg/kg/h) was
commenced. The triple regimen of xylocaine, propranolol,
and mexiletine was markedly effective. The patient was
successfully extubated and was administered oral medi-
cation of propranolol and mexiletine. He experienced no
further episodes of syncope or seizure on the regimen of
beta-blockers and mexiletine. His exercise test on the
regimen did not reach a deﬁnitive result owing to his
intolerance to the test. Invasive electrophysiological test-
ing was not performed. An implantable cardioverter-
deﬁbrillator (ICD) was not recommended because of the
risk of inappropriate shocks, which could provoke more
severe anxiety and possible ICD storms.pen access article under the CC BY-NC-ND license
http://dx.doi.org/10.1016/j.hrcr.2016.09.004
KEY TEACHING POINTS
 Mutations in the human calmodulin genes (CALM1,
CALM2, and CALM3) are associated with life-
threatening conditions in childhood, such as
idiopathic ventricular ﬁbrillation, long QT
syndrome (LQTS), and catecholaminergic
polymorphic ventricular tachycardia.
 An LQTS-speciﬁc “calmodulinopathy” phenotype
associated with CALMmutations has been described
with an early onset of the disease.
 Genetic testing for CALM mutations should be
performed in children with QT prolongation,
especially in those who have experienced an
aborted cardiac arrest and who have a negative
family history.
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Using the candidate gene approach, we initially screened the
authentic long QT syndrome genes KCNQ1, KCNH2,
SCN5A, and KCNE1 but found no mutation in them. When
screening for other candidate genes, we identiﬁed a novelFigure 1 A: Initial 12-lead electrocardiogram shows bidirectional premature v
Torsades de pointes with increasing heart rate.missense variation c.A3144C in exon 5 of CALM1. This
nucleotide change predicts the substitution of a conserved
glutamic acid residue with alanine (p.E105A) within the
third EF-hand calcium-binding motif in the C-terminal
domain of the encoded calmodulin protein (Figure 2). This
variation is not registered in any public DNA variation
databases, including the NHLBI GO Exome Sequencing
Project, 1000 Human Genome Project, Exome Aggregation
Consortium, and Japanese exome database HGVD (http://
www.genome.med.kyoto-u.ac.jp/SnpDB/. Accessed June
2016). In silico variant effect prediction programs Polyphen2
and SIFT gave the results “deleterious” (score 0) and
“probably damaging” (score 0.997), respectively.Clinical evaluation and genetic testing of family
members
The patient had 4 siblings: 3 sisters and 1 brother, aged 8–15
years. None had any known cardiac diseases or symptoms.
The parents and siblings had normal ECG indices, including
normal QTc intervals. Both parents turned out to be non-
carriers of CAML1-E105A, demonstrating that this is a de
novo mutation; therefore, we did not further investigate the
siblings.entricular beats. B: QT prolongation during sinus bradycardia at night. C:
Figure 2 A novel CALM1 mutation E105A. Upper panel indicates the sequence pherogram of the novel CALM1 missense mutation E105A. Lower panel
shows schematic representations of the Ca2þ binding loops in the N-terminal (I and II) and C-terminal (III and IV) and the locations of mutations. Red circle
represents the CALM1-E105A identiﬁed in our present study and green symbols represents CALM1 and CALM2 mutations previously reported.
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Here we described a case of aborted cardiac arrest in a
seemingly healthy preschool boy who exhibited profound
QT prolongation with an increasing heart rate before the
recurrence of polymorphic ventricular tachycardia at a
pediatric intensive care unit.
Therapy for a cardiac arrest survivor largely depends on
the underlying diagnosis, typically combining condition-
speciﬁc medication with an ICD. The management of the
patient’s family is driven by the outcome of a thorough
evaluation of the index cardiac arrest survivor. Therefore,
every effort should be made to determine the underlying
pathophysiology in order to clarify the prognosis and
establish the appropriate therapy. Genetic arrhythmia disor-
ders require further investigation of family members who
may be at risk.
As is characteristic of calmodulin gene mutations, the
patient had a negative family history of heart disease, and his
parents’ ECGs were normal. A cascade gene study was
conducted on the index case and his parents, and the results
were ﬁltered to include a novel sporadic variant in the
proband. Similar to other calmodulin mutations reported so
far, E105A is located at the acidic residues located at the EF
hands. It is speculated that E105A results in a substantial
reduction of Ca2þ afﬁnity, thereby disrupting the ability to
transduce intracellular Ca2þ signals and leading to lethal
arrhythmias, including severe catecholaminergic QT prolon-
gation and torsades de pointes. It is difﬁcult to identify
individuals susceptible to lethal arrhythmias during neonatal
ECG screening.
The patient also exhibited a developmental delay and mild
bronchial asthma as an extracardiac manifestation. Although
channelopathies in the brain are similar to the cardiac
channelopathies in some inherited arrhythmia disorders,10
the cause of the patient’s cognitive delay is unknown.
Although the follow-up thus far has been short term (18
months), this patient has successfully responded to beta-
blockade, the primary ﬁrst-line treatment for this disease.
Mexiletine therapy was added for the arrhythmia control in
the present case as well as in the previous cases published byCrotti et al.11 However, CALM-related calcium channel
dysfunction was proposed for the pathophysiological mech-
anism in calmodulionopathy.12–14 Therefore calcium antag-
onist may be a more beneﬁcial treatment of the choice. If the
patient continues to have syncope or arrhythmias on medi-
cation, he should be strongly considered for ICD implanta-
tion or cardiac sympathetic denervation to prevent life-
threatening arrhythmias because of his history of bronchial
asthma.Conclusions
We report a novel de novo CALM1 missense mutation
associated with a phenotype compatible with LQTS in a
child who experienced an aborted ﬁrst-episode cardiac arrest.
Genetic testing for CALM mutations should be performed in
children with QT prolongation, especially in those who have
experienced an aborted cardiac arrest and who have a
negative family history.References
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